Stockpolly
Search
Delisting risk
AIM · AMEX · Biotechnology

AIM ImmunoTech

Develops Ampligen as an immunotherapy adjunct for metastatic pancreatic cancer.

$0.2289
Pre-market−0.00 (−0.91%)
At close$0.2310(−10.60%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00000000000
Cost of revenue00000000000
Gross profit00000000000
146456432324
Research & development32112111101
114334312223
Selling & marketing00000000000
General & administrative114334312223
Other expenses00000000000
Operating income−14−6−4−4−6−4−3−2−3−2−4
1021000−1−1−10
Interest income00312003000
Interest expense00000000000
Other non-operating income−10−2−10001100
Income before tax−13−6−2−4−6−4−3−3−4−3−4
Net income from continuing operations−13−6−2−4−6−4−3−3−4−3−4
Net income−13−6−2−4−6−4−3−3−4−3−4
EPS, basic−$9.30−$4.27−$1.26−$2.33−$3.50−$1.91−$1.34−$1.57−$1.36−$0.69−$0.22
EPS, diluted−$9.30−$4.27−$1.26−$2.33−$3.50−$1.91−$1.34−$1.57−$1.36−$0.69−$0.22
Weighted average shares, basic———————23417
Weighted average shares, diluted———————23417
EBITDA−13−6−2−3−6−3−3−3−4−3−3
Depreciation & amortization00000000000
EBIT−13−6−2−3−6−4−3−3−4−3−3